BHVN
Biohaven Ltd.
Overview
Biohaven provides biopharmaceutical development and commercialization services, focusing on therapies in immunology, neuroscience, and oncology.
Biohaven Ltd is a Healthcare company operating in Biotechnology with a $2.04B market cap.
BHVN beat consensus EPS by 0.3% in Q1 FY2026, reported May 7, 2026.
4 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Earnings history
- Q1 FY20262026-05-07EPS$-0.69 vs $-1.04+33.7%Rev$0 vs ——EODHD
- Q4 FY20252026-03-18EPS$-0.90 vs $-1.18+23.7%Rev$0 vs ——EODHD
- Q3 FY20252025-11-09EPS$-1.64 vs $-1.88+12.8%Rev$0 vs ——EODHD
- Q2 FY20252025-08-10EPS$-1.94 vs $-1.940.0%Rev$0 vs ——EODHD
- Q1 FY20252025-05-11EPS$-2.17 vs $-1.70-27.7%Rev$0 vs ——EODHD
- Q4 FY20242025-03-02EPS$-1.71 vs $-1.60-6.9%Rev$3.8M vs ——EODHD
- Q3 FY20242024-11-11EPS$-1.74 vs $-1.70-2.4%Rev$0 vs ——EODHD
- Q2 FY20242024-08-08EPS$-3.50 vs $-1.78-96.6%Rev$0 vs ——EODHD
- Q1 FY20242024-05-08EPS$-2.20 vs $-1.57-40.1%Rev$0 vs ——EODHD
- Q4 FY20232024-02-28EPS$-1.81 vs $-1.41-28.4%Rev$0 vs ——EODHD
- Q3 FY20232023-11-13EPS$-1.50 vs $-1.34-11.9%Rev$0 vs ——EODHD
- Q2 FY20232023-07-30EPS$-1.32 vs $-1.21-9.1%Rev$0 vs ——EODHD
- Q1 FY20232023-05-11EPS$-1.03 vs $-1.41+27.0%Rev$0 vs ——EODHD
- Q4 FY20222023-03-22EPS$-3.32 vs $-1.22-100.0%Rev$-215.1M vs ——EODHD
- Q3 FY20222022-11-08EPS$-1.75 vs $-2.34+25.2%Rev$0 vs ——EODHD
- Q2 FY20222022-08-04EPS$-6.21 vs $-2.58-100.0%Rev$215.1M vs ——EODHD
- Q1 FY20222022-05-09EPS$-2.97 vs $-2.53-17.4%Rev$318.9M vs ——EODHD
- Q4 FY20212022-02-24EPS$-3.01 vs $-2.04-47.5%Rev$190.0M vs ——EODHD
- Q3 FY20212021-11-08EPS$-2.63 vs $-2.40-9.6%Rev$135.7M vs ——EODHD
- Q2 FY20212021-08-08EPS$-3.23 vs $-2.72-18.8%Rev$92.9M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-07 | $-0.69 | $-1.04 | +33.7% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-18 | $-0.90 | $-1.18 | +23.7% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-09 | $-1.64 | $-1.88 | +12.8% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-1.94 | $-1.94 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-2.17 | $-1.70 | -27.7% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-02 | $-1.71 | $-1.60 | -6.9% | $3.8M | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-1.74 | $-1.70 | -2.4% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-08 | $-3.50 | $-1.78 | -96.6% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-08 | $-2.20 | $-1.57 | -40.1% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-02-28 | $-1.81 | $-1.41 | -28.4% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-1.50 | $-1.34 | -11.9% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-07-30 | $-1.32 | $-1.21 | -9.1% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-11 | $-1.03 | $-1.41 | +27.0% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-22 | $-3.32 | $-1.22 | -100.0% | $-215.1M | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-1.75 | $-2.34 | +25.2% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-04 | $-6.21 | $-2.58 | -100.0% | $215.1M | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-2.97 | $-2.53 | -17.4% | $318.9M | — | — | EODHD |
| Q4 FY2021 | 2022-02-24 | $-3.01 | $-2.04 | -47.5% | $190.0M | — | — | EODHD |
| Q3 FY2021 | 2021-11-08 | $-2.63 | $-2.40 | -9.6% | $135.7M | — | — | EODHD |
| Q2 FY2021 | 2021-08-08 | $-3.23 | $-2.72 | -18.8% | $92.9M | — | — | EODHD |
Source: EODHD. BHVN reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks BHVN's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Misses consensus 10/10 quarters
SampleRepeated misses without a guidance reset suggest management is structurally optimistic relative to operating reality. Track whether next-quarter guidance is being benchmarked off the prior miss or the prior plan.
Missed in 4 of the last 4 quarters
SampleRecent misses matter more than long-window beat rate — the trailing 12 months drives the analyst model and the next-print bar.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2021 | $3.22 | $3.94 | -18.4% | +1.1% | -0.1% |
| Q4 FY2021 | $3.42 | $3.97 | -13.9% | -3.6% | -3.0% |
| Q3 FY2021 | $3.51 | $3.97 | -11.5% | +4.4% | +6.8% |
| Q2 FY2021 | $3.57 | $4.03 | -11.4% | -1.3% | +1.5% |
| Q1 FY2020 | $3.59 | $4.24 | -15.4% | +3.0% | +3.2% |
| Q4 FY2020 | $3.46 | $4.05 | -14.5% | +3.3% | +2.7% |
| Q3 FY2020 | $3.88 | $4.09 | -5.2% | +3.3% | +6.0% |
| Q2 FY2020 | $4.05 | $4.22 | -4.1% | 0.0% | +0.2% |
| Q1 FY2019 | $3.56 | $4.31 | -17.4% | +6.0% | +7.7% |
| Q4 FY2019 | $3.61 | $4.34 | -16.8% | +2.5% | +4.0% |
Guidance change history
Sample- Q1 FY2021Lowered2021-04-15
- Q4 FY2021Lowered2021-13-15
- Q3 FY2021Lowered2021-10-15
- Q2 FY2021Lowered2021-07-15
- Q1 FY2020Lowered2020-04-15
- Q4 FY2020Lowered2020-13-15
- Q3 FY2020Lowered2020-10-15
- Q2 FY2020Lowered2020-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Vlad CoricCEO1 yr 8 mo3 callsCurrentSample
CEO since 2024 • 1/2 beats (50%) • last guidance cut Q2 FY2021
- Matthew ButenCFO1 yr 5 mo1 callCurrentSample
CFO since 2025 • 1/2 beats (50%) • last guidance cut Q2 FY2021
- George C ClarkVP, Chief Accounting Officer1 yr 5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • last guidance raise Q1 FY2021
- Bruce CarChief Scientific Officer1 yr 5 mono recorded callsCurrentSample
OTHER_C_SUITE since 2025 • 1/2 beats (50%) • guidance suspended Q2 FY2021
- Kimberly GentileSVP, Clinical Operations1 yr 5 mono recorded callsCurrentSample
DIVISION_HEAD since 2025 • 2/2 beats (100%) • last guidance raise Q3 FY2021
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for BHVN.
$ curl https://api.spokenalpha.com/v1/companies/BHVNFAQ
Frequently asked about BHVN
Where can I find Biohaven Ltd.'s (BHVN) earnings call transcripts?
Spoken Alpha indexes BHVN's earnings call transcripts at https://spokenalpha.com/companies/BHVN. Each call links to attributed speakers and parsed analyst Q&A. Biohaven Ltd.'s own investor relations page is at https://ir.biohaven.com/.
When was Biohaven Ltd.'s most recent earnings call?
Biohaven Ltd. (BHVN) held its most recent earnings call on 2022-02-25, covering fiscal Q4 2021.
What sector is BHVN in?
Biohaven Ltd. (BHVN) operates in the Healthcare sector (Biotechnology industry).